Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Perspective Therapeutics ( (CATX) ) has issued an update.
Perspective Therapeutics has appointed Juan Graham as the new Chief Financial Officer, succeeding Jonathan Hunt who remains as Chief Accounting Officer. With nearly 25 years of experience in biopharmaceutical financial management, Graham’s expertise is expected to enhance the company’s strategic financial operations and support its growth, particularly as it advances its clinical programs and builds manufacturing infrastructure.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on pioneering advanced treatment applications for cancers throughout the body. The company utilizes the alpha-emitting isotope 212Pb to deliver targeted radiation to cancer cells via specialized targeting moieties and is also developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes.
YTD Price Performance: 6.04%
Average Trading Volume: 1,563,321
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $237.2M
For detailed information about CATX stock, go to TipRanks’ Stock Analysis page.
